Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.

Zhu J, Powis de Tenbossche CG, Cané S, Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P, Uyttenhove C, Van den Eynde BJ.

Nat Commun. 2017 Nov 10;8(1):1404. doi: 10.1038/s41467-017-00784-1.

2.

A new transcript in the TCRB locus unveils the human ortholog of the mouse pre-Dß1 promoter.

Lethé B, Snauwaert S, Bricard O, Schröder D, Gomard T, Hames G, Muller C, Lurquin C, Gauthy E, Essaghir A, Vandekerckhove B, Coulie PG.

Immun Inflamm Dis. 2017 Sep;5(3):346-354. doi: 10.1002/iid3.172. Epub 2017 May 15.

3.

Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.

Bourdeaux C, Lurquin C, Jacquemart I, Lethé B, Brasseur F, van Baren N, Baurain JF, Dyson J, Van Snick J, Uyttenhove C, Boon T.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3502-7. doi: 10.1073/pnas.1401115111. Epub 2014 Feb 18.

4.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

5.

A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice.

Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, Courtoy PJ, van der Bruggen P.

Cancer Res. 2010 Oct 1;70(19):7476-88. doi: 10.1158/0008-5472.CAN-10-0761. Epub 2010 Aug 18.

6.

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A, Boon T.

J Immunol. 2007 Mar 1;178(5):2617-21. No abstract available.

7.

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T.

J Exp Med. 2005 Jan 17;201(2):249-57.

8.

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Boon T, Coulie PG.

J Exp Med. 2005 Jan 17;201(2):241-8.

9.

Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.

Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethé B, Connerotte T, Corbière V, Demoitié MA, Liénard D, Dréno B, Velu T, Boon T, Coulie PG.

J Immunol. 2003 Nov 1;171(9):4898-904.

10.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T.

Immunol Rev. 2002 Oct;188:33-42. Review.

PMID:
12445279
11.

A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.

Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van der Bruggen P.

Tissue Antigens. 2002 Jul;60(1):16-24.

PMID:
12366779
12.

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.

Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Lévy F, Boon T, Van den Eynde BJ, van der Bruggen P.

J Exp Med. 2002 Feb 18;195(4):391-9.

13.

DNA microarray to monitor the expression of MAGE-A genes.

Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T, Remacle J.

Clin Chem. 2002 Jan;48(1):25-34.

14.

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10290-5. Epub 2001 Aug 21.

15.

Identification on a human sarcoma of two new genes with tumor-specific expression.

Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T.

Cancer Res. 2000 Jul 15;60(14):3848-55.

16.

A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.

Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P.

Eur J Immunol. 1999 Oct;29(10):3329-37.

17.

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.

De Smet C, Lurquin C, Lethé B, Martelange V, Boon T.

Mol Cell Biol. 1999 Nov;19(11):7327-35.

18.

Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries.

Serrano A, Lethé B, Delroisse JM, Lurquin C, De Plaen E, Brasseur F, Rimoldi D, Boon T.

Int J Cancer. 1999 Nov 26;83(5):664-9.

19.
20.

Identification of a new MAGE gene with tumor-specific expression by representational difference analysis.

Lucas S, De Smet C, Arden KC, Viars CS, Lethé B, Lurquin C, Boon T.

Cancer Res. 1998 Feb 15;58(4):743-52.

21.

Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins.

Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T.

Genomics. 1997 Dec 15;46(3):397-408.

PMID:
9441743
22.

Identification of human testis-specific transcripts and analysis of their expression in tumor cells.

De Smet C, Martelange V, Lucas S, Brasseur F, Lurquin C, Boon T.

Biochem Biophys Res Commun. 1997 Dec 29;241(3):653-7.

PMID:
9434763
23.

Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.

De Plaen E, Lurquin C, Lethé B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T.

Methods. 1997 Jun;12(2):125-42. Review.

PMID:
9184377
24.

Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.

De Smet C, Lurquin C, De Plaen E, Brasseur F, Zarour H, De Backer O, Coulie PG, Boon T.

Eye (Lond). 1997;11 ( Pt 2):243-8. Review.

PMID:
9349420
25.

Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.

Warnier G, Duffour MT, Uyttenhove C, Gajewski TF, Lurquin C, Haddada H, Perricaudet M, Boon T.

Int J Cancer. 1996 Jul 17;67(2):303-10.

26.

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T.

Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53.

27.

The IL-9 receptor gene (IL9R): genomic structure, chromosomal localization in the pseudoautosomal region of the long arm of the sex chromosomes, and identification of IL9R pseudogenes at 9qter, 10pter, 16pter, and 18pter.

Kermouni A, Van Roost E, Arden KC, Vermeesch JR, Weiss S, Godelaine D, Flint J, Lurquin C, Szikora JP, Higgs DR, et al.

Genomics. 1995 Sep 20;29(2):371-82.

PMID:
8666384
28.

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976-80.

29.

Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, Boon T.

Immunogenetics. 1995;42(4):282-90.

PMID:
7672823
30.

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T.

J Exp Med. 1994 Jul 1;180(1):35-42.

31.

Sequence and expression pattern of the human MAGE2 gene.

De Smet C, Lurquin C, van der Bruggen P, De Plaen E, Brasseur F, Boon T.

Immunogenetics. 1994;39(2):121-9.

PMID:
8276455
32.

Structure, chromosomal localization, and expression of 12 genes of the MAGE family.

De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethé B, Lurquin C, et al.

Immunogenetics. 1994;40(5):360-9.

PMID:
7927540
33.

Genes coding for tumor-specific rejection antigens.

Boon T, Van den Eynde B, Hirsch H, Moroni C, De Plaen E, van der Bruggen P, De Smet C, Lurquin C, Szikora JP, De Backer O.

Cold Spring Harb Symp Quant Biol. 1994;59:617-22. No abstract available.

PMID:
7587121
34.

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T.

J Exp Med. 1992 Nov 1;176(5):1453-7.

35.

Efficient expression of tum- antigen P91A by transfected subgenic fragments.

Chomez P, De Plaen E, Van Pel A, De Smet C, Szikora JP, Lurquin C, Lebacq-Verheyden AM, Boon T.

Immunogenetics. 1992;35(4):241-52.

PMID:
1541484
36.

Identification of tumour rejection antigens recognized by T lymphocytes.

Boon T, De Plaen E, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C, Amar-Costesec A, Van Pel A.

Cancer Surv. 1992;13:23-37. Review.

PMID:
1423324
37.

Tum- antigens, TSTA, and T cell immune surveillance.

Van Pel A, Warnier G, Van den Eynde B, Lethé B, Lurquin C, Boon T.

Ann N Y Acad Sci. 1991 Dec 30;636:43-51. Review. No abstract available.

PMID:
1793230
38.

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T.

Science. 1991 Dec 13;254(5038):1643-7.

PMID:
1840703
39.

Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

Lurquin C, Van Pel A, Mariamé B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T.

Cell. 1989 Jul 28;58(2):293-303.

PMID:
2568889
40.

Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.

Boon T, Van Pel A, De Plaen E, Chomez P, Lurquin C, Szikora JP, Sibille C, Mariamé B, Van den Eynde B, Lethé B, et al.

Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:587-96. Review. No abstract available.

PMID:
2700947
41.

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

De Plaen E, Lurquin C, Van Pel A, Mariamé B, Szikora JP, Wölfel T, Sibille C, Chomez P, Boon T.

Proc Natl Acad Sci U S A. 1988 Apr;85(7):2274-8.

42.

Identification of genes encoding T cell defined tum- antigens.

Van Pel A, De Plaen E, Lurquin C, Van den Eynde B, Lethé B, Hainaut P, Lemoine C, Boon T.

Princess Takamatsu Symp. 1988;19:255-63.

PMID:
3151988
43.

Supplemental Content

Loading ...
Support Center